

Top 10 Pharma Companies: Who is Recruiting?



Top 10 Pharma Companies: Who is Recruiting?

As the Pharmaceutical industry continues to grow, the big question is where the upcoming investments will take place?

Who is looking to cut back and who in the market is looking to grow?

What locations are the best for finding jobs? Is 2015 the right time to get your career started?

Pharma IQ team did some research and came up with this comprehensive guide on top employers in pharmaceutical industry.

Please note that the order is dictated by the Fortune 500 rank.

Authors and Contributors:



Chanice Henry
Editor at Pharma IQ




Luiza Samoraj
Digital Marketing Manager



Bristol-Myers Squibb

Johnson & Johnson



MERCK

Lilly



GILEAD

AMGEN

abbvie



biogen idec®

1. Johnson & Johnson



Revenues Millions \$	99751 \$
Profits Millions \$	16483 \$
Market Value (on March 31, 2014) Millions \$	200447 \$
Fortune 500 rank	39
Previous Rank	41

Source: www.fortune.com

CEO Alex Gorsky's future plans are to sustain growth through continued investment in research and development. Last year alone, the company invested over \$8 billion, or 11% of sales, to support R&D. Recent investments efforts are paying off: About 25% of sales came from products J&J brought to market in the past five years.

The Johnson & Johnson family of companies has had a significant presence in Ireland since 1935 and it looks like more investments in this area will take place in the future.

A division of Johnson & Johnson is to create up to 100 new IT jobs over the next two years through the creation of a development centre at the National Technology Park in Plassey, Co Limerick in Ireland.

Last April, Ethicon Biosurgery Ireland, part of the Johnson & Johnson family of companies announced plans to develop a €80m state-of-the-art manufacturing facility providing around 270 jobs, also at the National Technology Park, in Plassey, Co Limerick

Source: www.businessandleadership.com

2. Pfizer



Revenues Millions \$	\$53785
Profits Millions \$	\$ 22003
Market Value (on March 31, 2014) Millions \$	\$205360
Fortune 500 rank	51
Previous Rank	48

Source: www.fortune.com

Pfizer Inc. built itself into a \$212 billion behemoth by spending more money on acquisitions than any other drug maker in the world.

Pfizer will be making select headcount reductions in certain areas of R&D, and reallocating headcount to other growing areas of the organization. As Pfizer recently announced, the company has increased investment in areas that will position them to deliver on some of the most promising scientific advances.

Source: www.biopharmadive.com

The cutbacks at Pfizer follow one of the biggest restructurings in the industry, as the pharma giant carved billions of dollars out of its research budget.

On the other hand Pfizer is investing €145m at its Grange Castle biotechnology manufacturing site in Dublin that will enable it to introduce two new processing suites and expand current production and product testing capabilities. Source: www.idaireland.com

3. Merc & Co



Revenues Millions \$	\$44033
Profits Millions \$	\$ 4404
Market Value (on March 31, 2014) Millions \$	\$166939
Fortune 500 rank	65
Previous Rank	58

Source: www.fortune.com

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company has operations in pharmaceutical, animal health, and consumer care.

Pharmaceutical firm MSD has announced plans to close its plant in Swords in North Co Dublin by the end of 2017, which would result in the loss of 570 employees according to [RTE News](#). Richard Bruton said the phased closure of the plant was an unusual situation as it involved the merger of two large companies which created an excess capacity. He said that MSD's other facilities in Ireland were secure.

MSD announced that it is to invest €11.5 million in its Carlow site in 2015. In an announcement, the company didn't specifically outline how it would invest the money at the site where it has a 200,000-square-foot manufacturing facility, but Merck spokesperson said the "infrastructure" investment will include a training facility.

There are no new jobs coming at this time from the "phased project," the spokesperson said, but about 440 people currently work there.

Source: www.rte.ie

4. Eli Lilly & Co



Revenues Millions \$	\$23113
Profits Millions \$	\$ 4685
Market Value (on March 31, 2014) Millions \$	\$65906
Fortune 500 rank	129
Previous Rank	130

Source: www.fortune.com

Eli Lilly's drug portfolio and pipeline have changed significantly over the past decade. More than half of the company's pipeline now comprises biologics that require some type of injection. The company expects its revenues from device-enabled products to double by 2020.

Eli Lilly plans to establish a new drug delivery and device innovation center in Cambridge, Mass.—a strategic location it says will help attract top scientists and bioengineers, as well as enhance Eli Lilly's local business development presence.

Construction of the Lilly Cambridge Innovation Center already begun, with an expected occupancy by the end of 2015. Over the next two years, the company will hire about 30 scientists and engineers to fulfill the center's work.

When fully operational, the center will increase the company's delivery and device R&D space by nearly 50%, while increasing its staff by 25%. Source: www.centerwatch.com

5. Abbvie

abbvie

Revenues Millions \$	\$18790
Profits Millions \$	\$ 4128
Market Value (on March 31, 2014) Millions \$	\$81649
Fortune 500 rank	152
Previous Rank	-

Source: www.fortune.com

Chicago-based AbbVie (ABBV) will expand its operations in Puerto Rico to the tune of \$30 million and 100 new jobs over the next two years, the company said Wednesday, as it doubles down on the island as an increasingly source of manufacturing.

Chicago-based AbbVie (ABBV) will expand its operations in Puerto Rico. Abbvie is investing \$30 million in contract manufacturing facilities which will result in 100 new jobs over the next two years, as it doubles down on the island.

Following change in US law in 2010 which taxed big offshore tax earners, companies have started to pull out of the region. Pfizer and Merck plan to stop many of their operations in Barceloneta by 2017.

Novartis also announced that their Puerto Rican activity will come to an end and their manufacturing and packaging will be outsourced to Eli Lilly by 2019. Source: www.biospace.com

6. Amgen



Revenues Millions \$	\$18676
Profits Millions \$	\$ 5081
Market Value (on March 31, 2014) Millions \$	\$93122
Fortune 500 rank	154
Previous Rank	162

Source: www.fortune.com

Amgen Inc. is an independent biotechnology medicines company that discovers, develops, manufactures and markets medicines for grievous illnesses. The Company focuses solely on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology.

There will be many job cuts within Amgen in order to support drug launches this year.

Amgen announced that it will cut staff at its Conejo Valley headquarters and consolidate into fewer buildings as part of a company-wide restructuring plan that will eliminate between 2,400 and 2,900 jobs, predominately in the United States, and shutter facilities in Colorado and Washington. Source: www.pacbiztimes.com

Amgen said the layoffs and slashing of its facilities footprint by 23 % is designed to reduce operating expenses by \$700 million by 2016, money that it plans to reinvest to support new drug launches around the globe. The company said the cuts will constitute between 12 and 15 percent of its 20,000-member workforce. Amgen didn't specify how many of the cuts would come at Thousand Oaks, although a Business Times analysis suggests it could be as many as 1,800 or as few as none.

According to Robert A. Bradway, the Chief Executive and Chairman of Amgen, with four probable product launches and with a robust pipeline of biosimilar and innovative molecules, the company in 2015 are in an advantageous position to deliver a number of breakthrough medicines for the patients. This will ensure that long term growth will thrive. Source: www.financialbuzz.com

7. Bristol-Myers Squibb



Bristol-Myers Squibb

Revenues Millions \$	\$16385
Profits Millions \$	\$ 2563
Market Value (on March 31, 2014) Millions \$	\$85729
Fortune 500 rank	176
Previous Rank	158

Source: www.fortune.com

The US company has approved significant investment in Ireland. The first stage of funding for the project, with the full cost expected to be comparable to the roughly US\$900m investment to construct a similar facility in Devens, Massachusetts.

About 350 to 400 scientists, engineers, bioprocess operators, quality specialists and other skilled professionals are expected to work at the Dublin facility when construction is finished.

The completion of the Dublin facility, including commissioning and validation, is expected to take about four years and is estimated to be operational in 2019.

The 30,000-sq meter project will house six 15,000-litre bioreactors and a purification area as well as office and laboratory space. The plant will be built on the grounds of the company's existing bulk pharmaceutical manufacturing plant .Source: www.idaireland.com

8. Gilead Sciences



Revenues Millions \$	\$11202
Profits Millions \$	\$ 3075
Market Value (on March 31, 2014) Millions \$	\$109000
Fortune 500 rank	250
Previous Rank	280

Source: www.fortune.com

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.

Gilead Sciences is to create new UK commercial headquarters in London and expand its existing operations in the country.

The US biotech major is setting up home in Holborn and expanding its international operations in Uxbridge and UK R&D headquarters in Cambridge.

The moves represent an increased investment of \$19.6 million, doubling Gilead's UK workforce to 600 by the end of the year - 400 will be based in London.
Source: www.pharmatimes.com

9. Biogen Idec Inc.



Revenues Millions \$	\$6932
Profits Millions \$	\$ 1862
Market Value (on March 31, 2014) Millions \$	\$ 72305
Fortune 500 rank	375
Previous Rank	454

Source: www.fortune.com

Biogen is one of the world's oldest independent biotechnology companies, and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies.

Multiple sclerosis and hemophilia drug maker Biogen Idec (Nasdaq: BIIB) will add 100 workers to its operations in Research Triangle Park.

The announcement comes on the same day Biogen Idec reported 2014 revenues of \$9.7 billion, a 40 percent increase from 2013, and adds to the 1,300 workers already employed by the biotechnology company in the Triangle.

Biogen also produces treatments for hemophilia and has grown revenue and employment by more than 50 percent over the past three years and is expecting more growth in 2015, according to CEO George A. Scangos. Source: www.bizjournals.com

10. Celgene Corporation



Revenues Millions \$	\$6494
Profits Millions \$	\$ 1450
Market Value (on March 31, 2014) Millions \$	\$ 56680
Fortune 500 rank	401
Previous Rank	456

Source: www.fortune.com

Celgene Corporation is a global biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.

Another source of new jobs in the near future could be Celgene Corp., maker of cancer drug Revlimid, reported preliminary 2014 earnings that beat analysts' expectations and gave a optimistic forecast for long-term growth, saying sales will double in 2020 from this year.

Celgene expects to have \$20 billion in sales in 2020 as its hematology business grows to more than \$14.8 billion, the company said. With its new facility open in San Diego.
Source: www.bloomberg.com

Closing Remarks

As a job seeker, it's crucial to know which companies are hiring biopharmaceutical professionals as in-demand positions become available. Knowing the strategy of the company can help you to plan your career and ensure that you are making the best choice to suit your need.

Remember, job seekers need to know what their experience is worth! This can best be accomplished by being armed with facts in order to negotiate salary.



Good luck with getting your dream job!

Sources

- <http://fortune.com/fortune500/johnson-johnson-39/>
- <http://www.bloomberg.com/news/articles/2015-05-19/johnson-johnson-agrees-to-market-achillion-s-hepatitis-c-drugs>
- <http://www.businessandleadership.com/business/item/48599-johnson-and-johnson-to-create>
- <http://jacksonville.com/business/2015-05-06/story/johnson-johnson-proposes-300-million-100-job-expansion-jacksonville>
- <http://www.biopharmadive.com/news/pfizer-planning-more-layoffs-in-rd/367998/>
- <http://www.rte.ie/news/business/2013/1128/489745-msd-job-losses/>
- <http://www.centerwatch.com/news-online/article/7919/eli-lilly-plans-innovation-center-in-massachusetts#sthash.sxvOMyLG.dpuf>
- <http://www.pacbiztimes.com/2014/08/01/amgen-cuts-jobs-at-thousand-oaks-headquarters-as-drug-focus-narrows/#sthash.luCDP1Hf.dpuf>
- <http://www.nasdaq.com/article/amgen-to-cut-about-300-jobs-close-onyx-san-francisco-facility-20150311-00756>
- <https://www.siliconrepublic.com/careers/2014/11/14/400-jobs-set-for-new-bristol-myers-squibb-biologics-facility-in-cruiserath>
- http://www.pharmatimes.com/Article/15-02-10/Gilead_investing_%C2%A319_6_million_into_UK_expansion.aspx#ixzz3asbFlkFQ
- <http://www.bizjournals.com/triangle/news/2015/01/29/biogen-idec-biib-jobs-rtp-nc-ms-hemophilia-biotech.html?page=all>
- <http://www.bloomberg.com/news/articles/2015-01-12/celgene-sees-sales-doubling-by-2020-on-cancer-blood-treatments>